Auxilium Pharmaceuticals to Announce First Quarter 2008 Results and Conduct Conference Call on Wednesday, April 30,

MALVERN, PA, Apr 10 (MARKET WIRE) --
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical
company, will release results for the first quarter 2008 on Wednesday, April
30, 2008 before the opening of the financial markets. The Company will also
conduct a conference call that day at 10:00 a.m. ET to discuss results and
highlights of the first quarter 2008.

Mr. Armando Anido, Chief Executive Officer and President, will host the
conference call.

Conference call details:
Date: Wednesday, April 30, 2008
Time: 10:00 a.m. ET
Dial-in (U.S.): 866-202-4683
Dial-in (International): 617-213-8846
Web cast: http://www.auxilium.com
Passcode: AUXILIUM

To access an audio replay of the call:
Access number (U.S.): 888-286-8010
Access number (International): 617-801-6888
Replay Passcode #: 42186535

About Auxilium

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with
a
focus on developing and marketing to urologists, endocrinologists, orthopedists
and select
primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone
gel, for the treatment of hypogonadism through its approximately 190-person
sales
and marketing team. Auxilium has four projects in clinical development.
XIAFLEX(TM) (clostridial collagenase for injection), formerly referred to as
AA4500, is in phase III of development for the treatment of Dupuytren's
contracture
and is in phase II of development for the treatment of Peyronie's disease
and Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium's transmucosal
film
productcandidate for the treatment of overactive bladder (AA4010) is in phase I
ofdevelopment. The Company is currently seeking a partner to further
developthis product candidate. Auxilium has one pain product using its
transmucosal
film delivery system in pre-clinical development. Auxilium has rights to seven
additional pain products and products for hormone replacement and urologic
disease using its transmucosal film delivery system. Auxilium also has options
to
all indications using XIAFLEX for non-topical formulations. For additional
information, visit http://www.auxilium.com.

Safe Harbor Statement

This release contains "forward-looking-statements" within the meaning of The
Private Securities Litigation Reform Act of 1995, including statements regarding
the
Company's intention to announce the first quarter 2008 results; and products
in development for the treatment of Dupuytren's contracture, Peyronie's disease
and
Frozen Shoulder Syndrome and for pain, hormone replacement and urologic
disease. All statements other than statements of historical facts contained
in this release, including but not limited to, statements regarding future
expectations, plans and prospects for the Company, statements regarding
forward-looking financial information and other statements containing the words
"believe," "may," "could," "will," "estimate," "continue," "anticipate,"
"intend,"
"should," "plan," "expect," and similar expressions, as they relate to the
Company,constitute forward-looking statements. Actual results may differ
materiallyfrom those reflected in these forward-looking statements due to
various factors,
including general financial, economic, regulatory and political conditions
affecting the biotechnology and pharmaceutical industries and those discussed
in the Company's Annual Report on Form 10-K for the year ended December 31,
2007 under the heading "Risk Factors", which is on file with the Securities
and Exchange Commission (the "SEC") and may be accessed electronically by means
of
the SEC's home page on the Internet at http://www.sec.gov or by means of the
Company's home page on the Internet at http://www.auxilium.com under the heading
"Investor Relations - SEC Filings." There may be additional risks that the
Company does not presently know or that the Company currently believes are
immaterial which could also cause actual results to differ from those
contained in the forward-looking statements. Given these risks and
uncertainties, any or
all of these forward-looking statements may prove to be incorrect. Therefore,
you should not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide the Company's
expectations,plans or forecasts of future events and views as of the date of
this release.
The Company anticipates that subsequent events and developments will cause the
Company's assessments to change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the Company
specifically disclaims any obligation to do so. These forward-looking
statements should not be relied upon as representing the Company's
assessments as of any date subsequent to the date of this release.

For More Information, Contact:

James E. Fickenscher
CFO
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
Email Contact

William Q. Sargent, Jr.
V.P., Investor Relations
Auxilium Pharmaceuticals, Inc.
(484) 321-5926
Email Contact

Copyright 2008, Market Wire, All rights reserved.

-0-